drugset / Trial / NCT01316432

PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients

NCT01316432 ↗

Phase 1 Completed 58 enrolled Nile Therapeutics Integrium · collab
RandomizedSingle-groupSingle-blind

Summary

The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.

Timeline

Start
2011-05
Primary completion
2011-10
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenderitide Peptide — Subcutaneous